Trichlorodiphenylantimon | CAS:21907-22-2

We serve Trichlorodiphenylantimon CAS:21907-22-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Trichlorodiphenylantimon

Chemical Name:Trichlorodiphenylantimon
CAS.NO: 21907-22-2
Molecular Formula: C18H15Br2Sb
Molecular Weight: 512.88000
 
Synonyms:
Trichlorodiphenylantimon
Antimony trichloride, diphenyl-
Diphenyl-antimon(3+),Trichlorid
diphenylantimony trichloride
Diphenyl-antimon(3+),Tris-chlorid
biphenylantimony trichloride
diphenyl antimony (3+),tris chloride
 
 
Physical and Chemical Properties:
Melting point: /
 
 
 
Specification:
Appearance:Off-white crystal powder
Purity:≥95%
 
 
Packing:25kg/carton drum with plastic lining bag
Storage:Sealed storage, stored in a cool, dry warehouse. 
Application:chemical catalyst and fire retardant



Contact us for information like Potassium Chloride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,diphenyl antimony (3+),tris chloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Potassium selenocyanat Use and application,Potassium selenocyanat technical grade,usp/ep/jp grade.


Related News: These include: high-barrier generic drug substances and commonly used generic drug substances.(Benzotriazol-1-yloxy)dipiperidinocarbenium hexafluorophosphate manufacturer INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment.(4S)-3-[5-(4-Fluorophenyl)-1,5-dioxopenyl]-4-phenyl-2-oxazolidinone supplier INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment.5-(2-Fluorophenyl)-1H-pyrrole-3-carboxaldehyde vendor The market for pharmaceutical intermediates is vast and is expected to usher in new growth. Compared with the pesticide intermediate business, the market space for pharmaceutical intermediates is larger and will be the focus of the company’s future development.”Traditional medicine is a treasure of Chinese civilization embodying the wisdom of the nation and its people,” Xi said at the meeting in Beijing.